BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chiasma Raises $44 Million Series C To Fund Clinical Testing, Advance Technology


11/15/2006 9:42:22 AM

BOSTON--(BUSINESS WIRE)--Chiasma Inc., a privately held company developing novel technologies for the enhanced oral delivery of proteins and small molecules, announced today the completion of a $44 million Series C financing. The proceeds will be used to take three programs into clinical development and to advance the company's core technology.

The financing was led by MPM Capital, with participation by ARCH Venture Partners and existing investors Ofer Hi-tech Group and F-2 Ventures. As part of the financing, Drs. Ansbert Gadicke and Edward Scolnick of MPM Capital will join the company's board of directors and Robert Nelsen of ARCH Venture Partners will join the Board of Directors as an observer.

Dr. Edward Scolnick, Executive Advisor to MPM Capital, and former President of Merck Research Laboratories commented, "Chiasma's technology has the potential to revolutionize the oral delivery of protein- and peptide-based drugs. Poor absorption of these drugs currently require their injection by subcutaneous or IV means. Although early, Chiasma's technology for oral delivery could eventually have a very significant impact on the utilization and effectiveness of protein and peptide drugs."

Guy Yachin, President and CEO of Chiasma Inc., commented, "We are thrilled to have a syndicate of world class investors. MPM and ARCH bring not only financial resources, but also significant industry and entrepreneurial experience."

In addition to Drs. Gadicke and Scolnick, the Chiasma Board of Directors includes Guy Yachin, Chief Executive Officer; Raul Cesan, former Chief Operating Officer of Schering Plough; Dr. Dalia Megiddo of InnoMed Ventures; Dr. Bard Geesaman of F2 Ventures and MPM Capital; and Yoav Doppelt of Ofer Hi-tech Group.

About Chiasma Inc.

Chiasma Inc. is developing novel technologies for the enhanced oral delivery of proteins and small molecules. Chiasma was founded by Dr. Shmuel Ben Sasson, together with Guy Yachin and Dr. Dalia Megiddo of InnoMed Ventures. The company will be based in Boston, MA with a research subsidiary in Jerusalem, Israel.

About MPM Capital

MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston and San Francisco. MPM's portfolio ranges from start-ups to large capitalization public companies, with a primary focus on biopharmaceutical and medical device companies nearing commercialization of products or those companies that already offer product-driven opportunities. The firm manages over $2.4 billion in assets through the MPM BioVentures Family of venture capital funds and the MPM BioEquities public market funds. More information on MPM can be found at www.MPMCapital.com.

Contact: MPM Capital Christiana Goh Bardon, M.D., 617-425-9200

Source: Chiasma Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES